PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Narcolepsy

Drugs in development · updated 30 October 2026

Narcolepsy: drugs in development

As of 30 October 2026 there are 11 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for narcolepsy. 8 are experimental, that is not yet approved in the United States.

11Active trials
8Experimental drugs
5Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
ALKS 2680II–III2NCT06767683
CleminorextonII–III1NCT07598708
HBS-301III1NCT07675135
SamelisantIII1NCT07540364
TAK-861III1NCT07363720
E2086II1NCT07493265
ORX750II1NCT07096674
TAK-360II1NCT07633301

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
XywavIII1NCT07625280
Sodium oxybateLumryz®, Xyrem®II1NCT06809803

Sorted by most advanced phase and number of active trials.

All 10 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009290 “Narcolepsy”.

ItalianoFrançaisDeutsch